Randomized Study to Compare the Bioavailability of Two Augmented Betamethasone Dipropionate 0.05% Topical Creams

• Status: Completed
• Trial end date: 2003-01-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study was to compare the relative vasoconstrictive effects of test and reference topical augmented betamethasone dipropionate augmented 0.05% cream in healthy, female subjects.

• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Padagis LLC; Perrigo Company
• Treatments: Betamethasone; Betamethasone benzoate; Betamethasone sodium phosphate; Betamethasone Valerate; Betamethasone-17,21-dipropionate

Criteria

Inclusion Criteria:

• Non-tobacco-using female subjects, 18 to 50 years of age

• Demonstrated blanching response to Reference Drug (augmented betamethasone dipropionate) Cream 0.05%

• Weight within + or - 20% from normal for height and weight for body frame

• Good health as determined by lack of clinically significant abnormalities in medical history and clinical assessment, as judged by the Investigator

• Signed and dated informed consent form which meets all criteria of current FDA regulations

Exclusion Criteria:

• History of allergy to systemic or topical corticosteroids

• Presence of any skin condition or coloration that would interfere with the placement of test sites or the response or assessment of skin blanching

• Presence of medical condition requiring regular treatment with prescription drugs

• Drug or alcohol addiction requiring treatment in the past 12 months prior to dosing

• Use of any dermatological drug therapy on the flexor surface of the forearms within 30 days of dosing

• Use of any tobacco products in the 30 days prior to study dosing

• Receipt of any drugs as part of a research study within 30 days prior to study dosing

• Pregnant or lactating